Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ATL ULTRAMARK 9 WITH HDI: EXTENDED SIGNAL PROCESSING UPGRADE

This article was originally published in The Gray Sheet

Executive Summary

ATL ULTRAMARK 9 WITH HDI: EXTENDED SIGNAL PROCESSING UPGRADE deliveries will begin in June, Advanced Technology Laboratories, Inc. says in an April 19 release. The ESP upgrade to the Ultramark 9 with High Definition Imaging uses real-time parallel processing and system software to reduce "speckle noise," an artifact caused by "the random, artificial pattern of overlapping ultrasound echoes," according to ATL. The ESP option is being offered as part of a "level four" upgrade that also includes the C7-4 broadband curved array scanhead, the fifth addition to ATL's broadband scanhead line. The C7-4 provides "superior image quality" in obstetrical, superficial abdominal, and pediatric ultrasound examinations, ATL claims. The firm explains that the ESP parallel processing module and system software work together to "optimize the entire image formation path and extract further tissue information from the HDI broadband digital beamformer, without the compromises to image resolution required by conventional methodologies." The technology "more than doubles signal processing," and the resulting reduction of speckle noise "expands the potential of ultrasound to address diagnostic applications that were previously the domain of exploratory surgery and other more expensive or invasive imaging modalities," according to the firm. Benefits claimed for ESP include "enhanced visualization of subtle masses and tumors, clearer depiction of tissue changes associated with disease processes, more well-defined interfaces and tissue boundaries, greater confidence in the assessment of lesions and enhanced color Doppler for improved visualization of flow." The technology also provides "greater clarity of vessels and fluid-filled structures" and "improved characterization of arterial and venous disease states," ATL says. In addition, the "resolution of extremely fine detail" offered by the technology helps with imaging of small anatomical structures and early visualization of fetal development processes, according to the firm.

You may also be interested in...



ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

UsernamePublicRestriction

Register

MT000519

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel